Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | OTHER |
Not provided
Not provided
Not provided
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-678
This study is designed as single-center, single-dose, randomized, open-label and parallel-comparison to evaluate food effect on PK profile of TGRX-678 in healthy subjects. Safety and tolerability of the drug is also evaluated during study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fasting | Experimental | Participants take TGRX-678 under fasting state |
|
| Low-fat Diet | Experimental | Participants take TGRX-678 after low-fat meal intake |
|
| High-fat Diet | Experimental | Participants take TGRX-678 after high-fat meal intake |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TGRX-678 | Drug | All participants are given TGRX-678 orally at 240 mg |
|
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Tmax | Time to maximum concentration (Tmax) of TGRX-678 measured in plasma | During Treatment period (Day 1 to Day 43) |
| Plasma Tlag | Time between drug administration to drug absorption (Tlag) as indicated by TGRX-678 plasma concentration | During Treatment period (Day 1 to Day 43) |
| Plasma Cmax | Maximum concentration (Cmax) of TGRX-678 measured in plasma | During Treatment period (Day 1 to Day 43) |
| Plasma AUC(0-t) | Area Under drug concentration-time curve (AUC) from time 0 to last measureable timepoint for TGRX-678 as measured in plasma | During Treatment period (Day 1 to Day 43) |
| Plasma AUC(0-inf) | Area Under drug concentration-time curve from time 0 to infinity for TGRX-678 as measured in plasma | During Treatment period (Day 1 to Day 43) |
| AUC(%Extrap) | Calculated percentage of Area under curve for AUC(0-inf) that is from last measurable timepoint ot infinity, calculated based on TGRX-678 plasma concentration over time curve. | During Treatment period (Day 1 to Day 43) |
| Half Life (T1/2) | Time for TGRX-678 to decrease from maximum plasma concentration to half of maximum plasma concentration | During Treatment period (Day 1 to Day 43) |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events (AE) | To record adverse events to participants during study participation | Starting from consent signing and until end of Treatment period (Day 1 to Day 43) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Juan Li, MD | Nanjing Drug Tower Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nanjing Drum Tower Hospital | Nanjing | Jiangsu | 210008 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Plasma volume of distribution (Vz/F) | Apparent volume of distribution of TGRX-678 in plasma | During Treatment period (Day 1 to Day 43) |
| Plasma clearance (CL/F) | Apparent clearance of TGRX-678 in plasma | During Treatment period (Day 1 to Day 43) |
| D009196 |
| Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |